29.09.2021 CytoTools AG  DE000A0KFRJ1

DGAP-Adhoc: CytoTools AG considers complete change of Management Board and Supervisory Board possible as a result of the Annual General Meeting on 30.09.2021


 

DGAP-Ad-hoc: CytoTools AG / Key word(s): AGM/EGM/Personnel
CytoTools AG considers complete change of Management Board and Supervisory Board possible as a result of the Annual General Meeting on 30.09.2021

29-Sep-2021 / 15:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CytoTools AG considers complete change of Management Board and Supervisory Board possible as a result of the Annual General Meeting on 30.09.2021

Darmstadt, 29 September 2021 - CytoTools AG has invited to the ordinary (virtual) shareholders' meeting for September 30, 2021. Under agenda item 8, the Annual General Meeting is to vote on the proposal of a shareholder, Heidelberger Beteiligungsholding AG, on whether all incumbent members of the Supervisory Board are to be dismissed. Under agenda item 9, new candidates proposed by Heidelberger Beteiligungsholding AG are then to be elected to the Supervisory Board.

The incumbent members of the Management Board of CytoTools AG, Dr. Mark-Andre Freyberg and Dr. Dirk Kaiser, have decided today that they will not be available for an extension of their term of office as members of the Management Board in the event that the proposed resolution of Heidelberger Beteiligungsholding AG on agenda item 8 is adopted, so that their current appointment to the Management Board would end by rotation at the end of September 30, 2021.

CytoTools AG had already commented on the proposed resolutions of Heidelberger Beteiligungsholding AG in the notice convening the Annual General Meeting and pointed out that in the present case apparently not only a replacement of the entire Supervisory Board, but in the result also of the incumbent Management Board is intended anyway, so that there would be a simultaneous discontinuity on all management levels of CytoTools AG.

Although Heidelberger Beteiligungsholding AG and its affiliated companies or their majority shareholders do not hold the majority of shares in CytoTools AG, based on the registrations for the Annual General Meeting as well as the postal votes cast to date and the instructions issued to the proxies, CytoTools AG believes that there is an overwhelming probability that the proposed resolutions of Heidelberger Beteiligungsholding AG will find the required majority.


Contact:
CytoTools AG
Klappacher Straße 126
64285 Darmstadt
Telefax: +49 6151 9515813
Email: [email protected]


29-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CytoTools AG
Klappacher Str. 126
64285 Darmstadt
Germany
Phone: +49 (0)6151-951 58 12
Fax: +49 (0)6151-951 58 13
E-mail: [email protected]
Internet: www.cytotools.de
ISIN: DE000A0KFRJ1
WKN: A0KFRJ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1236837

 
End of Announcement DGAP News Service

1236837  29-Sep-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1236837&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 0,09 0,00 0,04 0,85 0,04 0,01 0,00
EBITDA1,2 -1,16 -0,92 -1,16 -3,00 -1,47 -0,82 0,00
EBITDA-Marge3 -1.288,89 0,00 -2.900,00 -352,94 -3.675,00 -8.200,00
EBIT1,4 -1,12 -1,22 -1,17 -3,10 -4,01 -0,82 0,00
EBIT-Marge5 -1.244,44 0,00 -2.925,00 -364,71 -10.025,00 -8.200,00 0,00
Jahresüberschuss1 -1,07 -1,42 -1,28 -3,30 -4,06 -0,83 0,00
Netto-Marge6 -1.188,89 0,00 -3.200,00 -388,24 -10.150,00 -8.300,00 0,00
Cashflow1,7 -1,15 -1,39 -1,26 -1,66 -1,56 -0,91 0,00
Ergebnis je Aktie8 -0,51 -0,53 -0,35 -0,46 -1,01 -0,16 -4,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Nexia

INVESTOR-INFORMATIONEN
©boersengefluester.de
BioXXmed
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0KFRJ 0,374 Verkaufen 1,92
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,82
KBV KCV KUV EV/EBITDA
1,28 - 160,12 -2,35
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 04.08.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.07.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-23,36% -68,86% -16,14% -84,80%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CytoTools AG  ISIN: DE000A0KFRJ1 können Sie bei EQS abrufen


Biotechnologie , A0KFRJ , T5O , XETR:T5O